The researchers at the Bengaluru-based Indian Institute of Science (IISc) have developed a new Covid-19 antibody test machine. The IISc developed a semi-quantitative electrochemical ELISA test for Covid-19. The test can determine levels of Covid-induced IgM and IgG antibodies.


  1. PathShodh Healthcare, a start-up incubated at the Society for Innovation and Development (SID), Indian Institute of Science (IISc), has made a significant breakthrough in developing a first-of-its-kind, semi-quantitative electrochemical ELISA test for COVID-19 IgM and IgG antibodies, IISc said.
  2. The Central Drugs Standard Control Organisation (CDSCO) after due diligence validation at the Translational Health Science and Technology Institute (THSTI), Faridabad – as per the requirements of the Indian Council of Medical Research (ICMR) – has issued a licence to manufacture the test for sale, and the scientists who are behind the project say they plan to deploy the product in the market.
  3. The novelty of the technology is based on the measurement of electrochemical redox activity of IgM and IgG antibodies specific to the SARS-CoV-2 Spike Glycoprotein (S1).
  4. The S1 protein has a Receptor Binding Domain (RBD) which latches on to the ACE2 receptors on the host cells before infection. Hence, antibody tests targeting the S1 spike protein are more representative of immune response against infection compared to those that target the Nucleocapsid (N) protein.
  5. This test has been developed by leveraging PathShodh’s Lab-on-Palm platform “anuPathTM”, which interfaces with disposable test strips functionalised with an immunoreceptor specific to Covid-19 antibodies.
  6. PathShodh is also developing a Covid-19 rapid antigen test on the same platform.